Growth hormone (GH) research and its clinical application for the treatment of growth
disorders span more than a century. During the first half of the 20th century, clinical …

PEGylation or covalent attachment of poly (ethylene glycol) improves the pharmacokinetic
properties of protein drugs. In vivo circulation lifetimes are increased and dosages are …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting
pituitary adenoma and leads to acromegaly—a disorder of disproportionate skeletal, tissue …

Background Patients with acromegaly are treated with surgery, radiation therapy, and drugs
to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have …

GH participates in growth, metabolism, and cellular differentiation. To study these roles, we
previously generated two different dwarf mouse lines, one expressing a GH antagonist …

GH has many biological roles, including promotion of growth. Most, if not all, of its roles are
achieved through interaction with its receptor. We chose to study the effects of loss of GH …

Human growth hormone (GH) is a classical pituitary endocrine hormone that is essential for
normal postnatal growth and has pleiotropic effects across multiple physiological systems …

I. Introduction H ETEROGENEITY of polypeptide hormones has been recognized since the
early 1970s. It stems from a variety of sources, including genetic, pretranslational …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …